WO1998047561A1 - Vorrichtung zum behandeln von malignen, tumorösen gewebebereichen - Google Patents
Vorrichtung zum behandeln von malignen, tumorösen gewebebereichen Download PDFInfo
- Publication number
- WO1998047561A1 WO1998047561A1 PCT/EP1998/002133 EP9802133W WO9847561A1 WO 1998047561 A1 WO1998047561 A1 WO 1998047561A1 EP 9802133 W EP9802133 W EP 9802133W WO 9847561 A1 WO9847561 A1 WO 9847561A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sensor
- active substance
- electrodes
- treatment
- sensors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
Definitions
- the invention relates to a device for treating malignant, tumorous tissue areas, with at least one measuring sensor for determining chemical or physical signal patterns in the immediate vicinity of the tumorous tissue area, with a control device and with at least one treatment device, the at least one active substance storage container Has metering device with metering control, an active substance delivery device for chemical influencing and / or electrodes for physical influencing of the tumorous tissue area to be treated and wherein the sensor or sensors, the active substance delivery device and the treatment electrodes are controlled with the control device for a dependence on the measured values of the tumor cells , physical and / or chemical treatment of the tumorous tissue area with continuous dosing tracking are associated with the active ingredient to be applied.
- chemotherapeutic agents which are intended to damage the pathogenic parts of the organ, but preferably not the rest of the organism.
- systemic and regional dosing of chemotherapeutic agents is problematic, since on the one hand a high level of effectiveness is aimed at, for example, a tumor, but on the other hand there is a risk of damage to healthy tissue due to unspecific intake.
- a system for detecting and treating cancer is known from the publication "BRINTON, J., B.: System to detect and treat cancer, using microwaves for both tasks. In: Elektronics, 1979, NO. 26, page 42". Tumors are localized using microwaves and then destroyed. In particular, with the help of a Radiometer uses the slightly elevated temperature in the area of a tumor for detection and thereby the tumor is recognized. It is a one-time, brief overheating and destruction of the tumor. Such treatment can be used for very small tumors, but this method cannot be used for larger tumor areas.
- DE 196 01 487 discloses a device for use in areas that are directly or operatively accessible. However, such a device cannot be used for areas that are not to be opened operationally.
- the object of the present invention is to provide a device with which target-oriented medication can be dispensed, in which the stress and damage to the unaffected areas of the body are at least largely reduced
- the device be designed capsule-shaped or dragee-shaped for swallowing and has a covering that at least covers the sensor or sensors, that the covering can be at least partially dissolved (removed) under the influence of body fluid and that a sensor for Detection of triggering parameters and the control device are designed by means of a threshold switch for activating the active substance delivery device and / or the electrodes when a predetermined or predeterminable target value is exceeded.
- the capsule or coated tablet is in front of the Swallowing becomes inactive and only becomes active when the wrapping is dissolved.
- the wrapper also practically forms a protective wrapper, which is advantageous for longer storage before the treatment.
- the covering can be released from the body fluid in particular depending on the time and / or substance.
- the position of the device within the digestive tract when it is activated and also the activation time can be predetermined with sufficient accuracy.
- different digestive juices act on the casing, so that through targeted selection of the casing material it can be determined under which digestive juice the device should be activated.
- the duration of the activation process can also be predetermined by the covering material and its thickness.
- the device according to the invention can also be used for target-oriented medication delivery by oral ingestion in gastric and intestinal diseases, for example by targeted alkali delivery or the delivery of another active substance.
- the triggering parameters for the start of the treatment can be the pH value, which is continuously measured, for example, and which triggers the treatment, in particular by delivering active ingredients, if there is a deviation from a predetermined value. Except for example mentioned pH value measurement, a lactate measurement, a calcium measurement, an impedance measurement and the like can also be carried out.
- a medicinal agent can be applied for chemical influencing and at the same time there is ongoing monitoring in the immediate vicinity of the treatment site with the help of the sensor or sensors during the treatment.
- the dosage can be adjusted by the control device in accordance with the setpoint values.
- An independently working control loop is thus formed, by means of which the dosage of the active substance to be applied can be continuously updated.
- the active substance release during a chemical treatment and / or the intensity during the physical treatment is controlled as a function of a measured value.
- the treatment is carried out by measuring triggering parameters, for example the pH value. This also means that the treatment ceases when a threshold value is undershot.
- the protective sheath is first removed, so that the sensor or sensors are then exposed and are capable of predefinable triggering parameters capture. If the capsule m reaches the area of malignant, tumorous tissue in this activated state, this is recognized on the basis of, for example, the pH value and, depending on the deviation of the pH value from the normal pH value m of this body environment, becomes a chemical and / or physical Treatment carried out in a regulated manner. If the capsule is transported further and emerges from the area of the tumorous tissue to be treated, the treatment is reduced and finally stopped.
- One embodiment of the invention provides that, at least to increase the length of time the capsule or dragee stays at the treatment site, it has a coating with a filler or foaming system, in particular on an enzymatic basis, which is used for an immunobiochemical and / or immuno-enzymatic reaction when inflammation is reached - or tumorous site is formed.
- the corresponding reaction causes the filling material of the capsule to dock onto the relevant location and, if necessary, causes a foaming or swelling and thus an increase in volume through a chemical reaction.
- the foaming or swelling material preferably has certain adhesive properties, which also contributes to increasing the residence time.
- the device can have electrodes on the outside for galvanic current generation when it comes into contact with body fluid.
- Carrying a battery for the power supply is therefore not necessary, so that space can be saved accordingly or is available for other facilities.
- the battery-free version is preferred, it can be provided in special cases, possibly also as a buffer battery in connection with electrodes for generating electricity when in contact with body fluid or a charging coil.
- At least one sensor for determining the acidification or another parameter in the treatment area is provided, since changes in the pH value, for example, allow conclusions to be drawn about the metabolic activities of the tumor cells and thus appropriate treatment adjustments can be made. This is based on the finding that tumor growth and spread must be viewed as a process of cellular self-organization that, apart from changes in the cellular signal processing apparatus, is essentially controlled by the microenvironment of the tumor.
- the pH of the microenvironment of the tumor can play a key role here.
- control device based on the measurement of the existing pH value as the actual value, regulates the dosage of the medicinal active ingredient until the setpoint, in the example pH 7.4, is reached.
- the medicinal active substance can be an active substance for neutralizing the pH gradient.
- An active ingredient (antagonist) for blocking the proton pump on the cell membranes of the tumor cells or an active ingredient for blocking the molecular biological agents (for example antisense products) are also possible.
- a physical influencing can also be carried out. This can be done by means of electrical and / or electromagnetic fields via electrodes on the device by means of iontophoresis. A direct voltage or an alternating voltage can be applied to the electrodes.
- the field m is changed as a function of the respective measured value, so that a control loop and thus a targeted treatment with "feedback" is also available in this regard.
- a semiconductor-based pH sensor or a pH sensor based on a conductivity and impedance measurement can be provided in the vicinity of the tumor cells, preferably at least one for a semiconductor-based pH sensor Ion-selective field effect transistor (IS-FET) is provided.
- IS-FET semiconductor-based pH sensor Ion-selective field effect transistor
- At least one further sensor in particular an ion or molecular sensor, is provided in addition to at least one pH sensor.
- additional sensors in addition to pH changes, additional, therapy-relevant changes in the microenvironment of a tumor can be recorded, and corresponding measures when applying the medicinal active substance can be derived from these additional measurement data.
- the active substance delivery device expediently has at least one porous membrane and an active substance supply to this membrane, a metering device being located in the active substance supply and being connected to a metering control.
- the membrane can optionally be modified chemically so that it adheres preferentially to the area to be treated.
- the sensor or sensors as well as the porous membrane that may be provided form a support and contact surface for the tissue area to be treated.
- At least two electrodes for iontophoretic purposes can also be provided, which are connected to a voltage source via electrical lines. This enables a regionally limited and dosed supply of active ingredient.
- An embodiment of the invention provides that at least one heating resistor for within the active substance storage container Heating and delivery of active ingredient is provided.
- the active substance storage container can preferably have at least one capillary for dispensing the active substance.
- the liquid expands and is released from the storage container in the direction of the contact and contact surface.
- the functional unit has at least one active substance storage container, one or more metering device (s) connected to the porous membrane or the like with metering control and at least one pH sensor.
- FIG. 1 to 3 schematic representations of a device according to the invention in different embodiments, each with three sandwich-like assemblies,
- Fig. 4 is a schematic side view of another embodiment of a device according to the invention.
- Fig. 5 is a schematic side view of a further modified embodiment of a device according to the invention.
- a container 4 for receiving an active substance is connected to the control chip 2 and is connected to an active substance delivery device 6 via a connecting channel 5.
- This device 6 has a delivery window 8, which is preferably formed by a porous membrane 7. Adjacent to the delivery window 8 are sensors 9, at least one of which is a pH sensor, by means of which the pH of the area to be treated can be monitored.
- the assemblies 2, 4 and 6 can be designed as preferably approximately equal-area components which have contact pads 10 on their mutually facing sides, by means of which the assemblies can preferably be connected to one another by means of flip-chip technology.
- the unit consisting of the individual assemblies has a covering 11 which can be dissolved from the body fluid as a function of time and / or substance.
- the material composition of this covering 11 is provided depending on where the device 1 is to be activated within the digestive tract. In particular, a coordination to the different body fluids acting within the digestive tract is also provided.
- a covering which is different in terms of the material and which is composed differently in the area of the electrodes 3 than in the area opposite, where the dispensing window and the sensors are located.
- the sheath 11 at the electrodes 3 for power generation is first dissolved, so that the device is then ready for operation. If the covering is then also dissolved in the area of the delivery window 8 and the sensors 9, the treatment begins, for example, by the targeted delivery of active substance at the delivery window 8.
- the capsule 12 has an inner protective covering 13, which acts in the area of the outside Parts - electrodes, sensors, delivery windows - have corresponding interruptions.
- FIG. 1 shows a further embodiment of a device 1 a, which is also designed as a capsule 12.
- a three-layer structure is provided with the aid of three chips 14, 15, 16.
- a correspondingly dimensioned distance is provided between the chip 14 arranged on the outside and the chip 15 adjacent thereto, a correspondingly dimensioned distance is provided to form the active substance storage container 4 and a circumferential sealing ring 17 between these two chips 14 and 15 serves as a spacer.
- This covering with or from the corresponding material reacts immunobiochemically or immuno-enzymatically when an inflammatory site or a tumorous site is reached.
- the capsule 12a can thereby be determined at the treatment site or at least increased their stay there.
- the foaming with a corresponding increase in volume which can also temporarily stick in the treatment area, at least impedes the further transport of the capsule 12a within the digestive tract, so that a sufficiently long treatment time is available.
- FIG. 4 shows another modified embodiment of a device 1c, which is also designed in the shape of a cap. However, the arrangement of the individual modules differs from the other exemplary embodiments.
- the device 1c also has an active substance storage container 4 which has dispensing openings 24 in the region of reference electrodes 3.
- An electronics part with the control device for the physical and / or chemical treatment and the processing of the measured values coming from the sensor or sensors is located at a head end of the capsule.
- the sensor or sensors 9 are located on an end outer end of the capsule in the electronic part 25.
- FIG. 5 A further modified embodiment is shown in FIG. 5.
- m is the drug reservoir 4.
- a cavern as a storage container 4 and also a capillary channel 19 can be etched into the chip.
- the capillary channel 19 leads to a delivery window 8a, through which the active ingredient is delivered to the outside.
- the delivery window 8a with control valve and metering control can be designed as a separate chip.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54494798A JP2001523996A (ja) | 1997-04-23 | 1998-04-11 | 悪性腫瘍組織領域を治療する装置 |
DE59812897T DE59812897D1 (de) | 1997-04-23 | 1998-04-11 | Vorrichtung zum behandeln von malignen, tumorösen gewebebereichen |
EP98921456A EP0977614B1 (de) | 1997-04-23 | 1998-04-11 | Vorrichtung zum behandeln von malignen, tumorösen gewebebereichen |
US09/425,598 US6245057B1 (en) | 1997-04-23 | 1999-10-22 | Device for treating malignant, tumorous tissue areas |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19717023.4 | 1997-04-23 | ||
DE19717023A DE19717023C2 (de) | 1997-04-23 | 1997-04-23 | Vorrichtung zum Behandeln von malignen, tumorösen Gewebebereichen |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/425,598 Continuation US6245057B1 (en) | 1997-04-23 | 1999-10-22 | Device for treating malignant, tumorous tissue areas |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998047561A1 true WO1998047561A1 (de) | 1998-10-29 |
Family
ID=7827425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/002133 WO1998047561A1 (de) | 1997-04-23 | 1998-04-11 | Vorrichtung zum behandeln von malignen, tumorösen gewebebereichen |
Country Status (5)
Country | Link |
---|---|
US (1) | US6245057B1 (de) |
EP (1) | EP0977614B1 (de) |
JP (1) | JP2001523996A (de) |
DE (2) | DE19717023C2 (de) |
WO (1) | WO1998047561A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112007279A (zh) * | 2019-05-30 | 2020-12-01 | 淡海高级化妆品实验有限公司 | 手持抗皱的装置及皮肤护理的系统 |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8636648B2 (en) * | 1999-03-01 | 2014-01-28 | West View Research, Llc | Endoscopic smart probe |
US10973397B2 (en) | 1999-03-01 | 2021-04-13 | West View Research, Llc | Computerized information collection and processing apparatus |
US7747477B1 (en) | 2000-11-16 | 2010-06-29 | Gsl Solutions, Inc. | Pharmacy supply tracking and storage system |
US8224664B1 (en) | 2000-11-16 | 2012-07-17 | Gsl Solutions, Inc. | Portable prescription order distribution cart and tracking system |
US7887146B1 (en) * | 2001-08-18 | 2011-02-15 | Gsl Solutions, Inc. | Suspended storage system for pharmacy |
US20090230189A1 (en) * | 2000-11-16 | 2009-09-17 | Shelton Louie | Scanning Wand For Pharmacy Tracking and Verification |
US8479988B2 (en) * | 2000-11-16 | 2013-07-09 | Gsl Solutions, Inc. | System for pharmacy tracking and customer id verification |
AT411150B (de) * | 2001-05-25 | 2003-10-27 | Nova Technical Res Gmbh | Einrichtung zum einbringen von stoffen |
US7708712B2 (en) * | 2001-09-04 | 2010-05-04 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in a body organ |
IL147221A (en) | 2001-12-20 | 2010-11-30 | Given Imaging Ltd | Device, system and method for image based size analysis |
US20040267240A1 (en) * | 2003-01-29 | 2004-12-30 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
WO2004066903A2 (en) * | 2003-01-29 | 2004-08-12 | E-Pill Pharma Ltd. | Active drug delivery in the gastrointestinal tract |
US20050058701A1 (en) * | 2003-01-29 | 2005-03-17 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
WO2004083797A2 (en) * | 2003-03-14 | 2004-09-30 | Thermosurgery Technologies, Inc. | Hyperthermia treatment system |
US20040193023A1 (en) * | 2003-03-28 | 2004-09-30 | Aris Mardirossian | System, method and apparatus for monitoring recording and reporting physiological data |
US8308682B2 (en) | 2003-07-18 | 2012-11-13 | Broncus Medical Inc. | Devices for maintaining patency of surgically created channels in tissue |
US7554452B2 (en) * | 2003-07-18 | 2009-06-30 | Cary Cole | Ingestible tracking and locating device |
EP1673812A2 (de) * | 2003-07-19 | 2006-06-28 | Infineon Technologies AG | Integrierte sensor-chip-einheit |
EP3851030B1 (de) | 2003-09-11 | 2024-01-17 | Labrador Diagnostics LLC | Medizinische vorrichtung zur analytenüberwachung |
US8409167B2 (en) | 2004-07-19 | 2013-04-02 | Broncus Medical Inc | Devices for delivering substances through an extra-anatomic opening created in an airway |
US20080275430A1 (en) * | 2004-12-14 | 2008-11-06 | Ziv Belsky | Prolonged Transit Time of Permeability-Enhancing Drug Eluting Pill |
WO2006077527A2 (en) * | 2005-01-18 | 2006-07-27 | Koninklijke Philips Electronics, N.V. | Electronically controlled capsule for releasing radiation |
US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
CN101287411B (zh) | 2005-04-28 | 2013-03-06 | 普罗秋斯生物医学公司 | 药物信息系统及其用途 |
US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
US8730031B2 (en) | 2005-04-28 | 2014-05-20 | Proteus Digital Health, Inc. | Communication system using an implantable device |
US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
US20060264783A1 (en) | 2005-05-09 | 2006-11-23 | Holmes Elizabeth A | Systems and methods for monitoring pharmacological parameters |
JP2008540023A (ja) * | 2005-05-19 | 2008-11-20 | イー−ピル ファーマ リミティド | 組織における一酸化窒素生成のための摂取可能デバイス |
JP2006334164A (ja) * | 2005-06-02 | 2006-12-14 | Transcutaneous Technologies Inc | イオントフォレーシス装置及びその制御方法 |
JP2007037868A (ja) * | 2005-08-05 | 2007-02-15 | Transcutaneous Technologies Inc | 経皮投与装置及びその制御方法 |
US8547248B2 (en) | 2005-09-01 | 2013-10-01 | Proteus Digital Health, Inc. | Implantable zero-wire communications system |
US20070071807A1 (en) * | 2005-09-28 | 2007-03-29 | Hidero Akiyama | Capsule-type drug-releasing device and capsule-type drug-releasing device system |
BRPI0616487A2 (pt) * | 2005-09-30 | 2011-06-21 | Tti Ellebeau Inc | aparato e método de iontoforese para liberação sistêmica de agentes ativos |
US20070078445A1 (en) * | 2005-09-30 | 2007-04-05 | Curt Malloy | Synchronization apparatus and method for iontophoresis device to deliver active agents to biological interfaces |
WO2007041115A1 (en) * | 2005-09-30 | 2007-04-12 | Tti Ellebeau Inc. | Method and system to detect malfunctions in an iontophoresis device that delivers active agents to biological interfaces |
EP1965858A2 (de) * | 2005-12-30 | 2008-09-10 | Tti Ellebeau, Inc. | System und verfahren zur fernsteuerung eines iontophoresegerätes |
US11287421B2 (en) | 2006-03-24 | 2022-03-29 | Labrador Diagnostics Llc | Systems and methods of sample processing and fluid control in a fluidic system |
US8741230B2 (en) | 2006-03-24 | 2014-06-03 | Theranos, Inc. | Systems and methods of sample processing and fluid control in a fluidic system |
CN105468895A (zh) | 2006-05-02 | 2016-04-06 | 普罗透斯数字保健公司 | 患者定制的治疗方案 |
US8007999B2 (en) | 2006-05-10 | 2011-08-30 | Theranos, Inc. | Real-time detection of influenza virus |
JP2009538671A (ja) * | 2006-06-02 | 2009-11-12 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 物質の制御放出のための装置 |
WO2008027440A2 (en) * | 2006-08-29 | 2008-03-06 | Tti Ellebeau, Inc. | An iontophoresis device and method for operation with a usb (universal serial bus) power source |
BRPI0716452A2 (pt) | 2006-09-05 | 2014-03-04 | Tti Ellebeau Inc | Sistemas não destrutivos, dispositivos, e métodos para avaliar dispositivos de distribuição de medicamentos de iontoforese |
BRPI0716450A2 (pt) | 2006-09-05 | 2014-03-11 | Tti Ellebeau Inc | Sistemas, dispositivos e métodos de impedância para avaliar propriedades iontoforéticas de compostos |
US8012744B2 (en) | 2006-10-13 | 2011-09-06 | Theranos, Inc. | Reducing optical interference in a fluidic device |
ATE535057T1 (de) | 2006-10-17 | 2011-12-15 | Proteus Biomedical Inc | Niederspannungsoszillator für medizinische einrichtungen |
SG175681A1 (en) | 2006-10-25 | 2011-11-28 | Proteus Biomedical Inc | Controlled activation ingestible identifier |
US20080113391A1 (en) * | 2006-11-14 | 2008-05-15 | Ian Gibbons | Detection and quantification of analytes in bodily fluids |
WO2008063626A2 (en) | 2006-11-20 | 2008-05-29 | Proteus Biomedical, Inc. | Active signal processing personal health signal receivers |
TW200838576A (en) | 2006-12-01 | 2008-10-01 | Transcu Ltd | Systems, devices and methods for powering and/or controlling transdermal delivery devices |
CA2676407A1 (en) * | 2007-02-01 | 2008-08-07 | Proteus Biomedical, Inc. | Ingestible event marker systems |
CN101636865B (zh) | 2007-02-14 | 2012-09-05 | 普罗秋斯生物医学公司 | 具有高表面积电极的体内电源 |
US9270025B2 (en) | 2007-03-09 | 2016-02-23 | Proteus Digital Health, Inc. | In-body device having deployable antenna |
US8932221B2 (en) | 2007-03-09 | 2015-01-13 | Proteus Digital Health, Inc. | In-body device having a multi-directional transmitter |
US8540632B2 (en) | 2007-05-24 | 2013-09-24 | Proteus Digital Health, Inc. | Low profile antenna for in body device |
US8158430B1 (en) | 2007-08-06 | 2012-04-17 | Theranos, Inc. | Systems and methods of fluidic sample processing |
DK2192946T3 (da) | 2007-09-25 | 2022-11-21 | Otsuka Pharma Co Ltd | Kropsintern anordning med virtuel dipol signalforstærkning |
US8088593B2 (en) | 2007-10-02 | 2012-01-03 | Theranos, Inc. | Modular point-of-care devices, systems, and uses thereof |
EP3235491B1 (de) | 2008-03-05 | 2020-11-04 | Proteus Digital Health, Inc. | Verzehrbare marker und system für multimodale kommunikationsereignisse |
SG10201702853UA (en) | 2008-07-08 | 2017-06-29 | Proteus Digital Health Inc | Ingestible event marker data framework |
US8287902B2 (en) * | 2008-07-23 | 2012-10-16 | Rainbow Medical Ltd. | Enhanced-diffusion capsule |
AU2009281876B2 (en) | 2008-08-13 | 2014-05-22 | Proteus Digital Health, Inc. | Ingestible circuitry |
JP5411943B2 (ja) | 2008-11-13 | 2014-02-12 | プロテウス デジタル ヘルス, インコーポレイテッド | 摂取可能な治療起動装置システムおよび方法 |
AU2009324536A1 (en) | 2008-12-11 | 2011-07-14 | Proteus Digital Health, Inc. | Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same |
TWI503101B (zh) | 2008-12-15 | 2015-10-11 | Proteus Digital Health Inc | 與身體有關的接收器及其方法 |
US9659423B2 (en) | 2008-12-15 | 2017-05-23 | Proteus Digital Health, Inc. | Personal authentication apparatus system and method |
US9439566B2 (en) | 2008-12-15 | 2016-09-13 | Proteus Digital Health, Inc. | Re-wearable wireless device |
SG196787A1 (en) | 2009-01-06 | 2014-02-13 | Proteus Digital Health Inc | Ingestion-related biofeedback and personalized medical therapy method and system |
SG172847A1 (en) | 2009-01-06 | 2011-08-29 | Proteus Biomedical Inc | Pharmaceutical dosages delivery system |
GB2480965B (en) | 2009-03-25 | 2014-10-08 | Proteus Digital Health Inc | Probablistic pharmacokinetic and pharmacodynamic modeling |
DE102009017662B4 (de) * | 2009-04-16 | 2016-11-10 | Hochschule Offenburg | Elektronische Pille zur steuerbaren Abgabe einer Substanz, insbesondere eines Medikaments, in einem menschlichen oder tierischen Körper |
SG10201810784SA (en) | 2009-04-28 | 2018-12-28 | Proteus Digital Health Inc | Highly Reliable Ingestible Event Markers And Methods For Using The Same |
US20100286587A1 (en) * | 2009-05-07 | 2010-11-11 | Yossi Gross | Sublingual electrical drug delivery |
US20100286628A1 (en) * | 2009-05-07 | 2010-11-11 | Rainbow Medical Ltd | Gastric anchor |
US8414559B2 (en) * | 2009-05-07 | 2013-04-09 | Rainbow Medical Ltd. | Gastroretentive duodenal pill |
US20110066175A1 (en) * | 2009-05-07 | 2011-03-17 | Rainbow Medical Ltd. | Gastric anchor |
US9149423B2 (en) | 2009-05-12 | 2015-10-06 | Proteus Digital Health, Inc. | Ingestible event markers comprising an ingestible component |
WO2011022732A2 (en) | 2009-08-21 | 2011-02-24 | Proteus Biomedical, Inc. | Apparatus and method for measuring biochemical parameters |
US20110077718A1 (en) * | 2009-09-30 | 2011-03-31 | Broadcom Corporation | Electromagnetic power booster for bio-medical units |
EP2491499A4 (de) | 2009-10-19 | 2016-05-18 | Theranos Inc | Integriertes system zur erfassung und analyse von gesundheitsdaten |
TWI517050B (zh) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | 供應鏈管理之系統 |
UA109424C2 (uk) | 2009-12-02 | 2015-08-25 | Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки | |
CN102946798A (zh) | 2010-02-01 | 2013-02-27 | 普罗秋斯数字健康公司 | 数据采集系统 |
TWI638652B (zh) | 2010-04-07 | 2018-10-21 | 波提亞斯數位康健公司 | 微型可攝取裝置 |
TWI557672B (zh) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置 |
WO2012071280A2 (en) | 2010-11-22 | 2012-05-31 | Proteus Biomedical, Inc. | Ingestible device with pharmaceutical product |
CN111982829A (zh) | 2011-01-21 | 2020-11-24 | 拉布拉多诊断有限责任公司 | 样品使用最大化的系统和方法 |
US11244747B2 (en) | 2014-10-16 | 2022-02-08 | Gsl Solutions, Inc. | Pharmacy security system |
JP2014514032A (ja) | 2011-03-11 | 2014-06-19 | プロテウス デジタル ヘルス, インコーポレイテッド | 様々な物理的構成を備えた着用式個人身体関連装置 |
US8709034B2 (en) | 2011-05-13 | 2014-04-29 | Broncus Medical Inc. | Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall |
US9345532B2 (en) | 2011-05-13 | 2016-05-24 | Broncus Medical Inc. | Methods and devices for ablation of tissue |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
CN103827914A (zh) | 2011-07-21 | 2014-05-28 | 普罗秋斯数字健康公司 | 移动通信设备、系统和方法 |
US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
WO2013078235A1 (en) | 2011-11-23 | 2013-05-30 | Broncus Medical Inc | Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall |
BR112015001388A2 (pt) | 2012-07-23 | 2017-07-04 | Proteus Digital Health Inc | técnicas para fabricar marcadores de eventos ingeríveis que compreendem um componente ingerível |
AU2013331417B2 (en) | 2012-10-18 | 2016-06-02 | Proteus Digital Health, Inc. | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
TWI659994B (zh) | 2013-01-29 | 2019-05-21 | 美商普羅托斯數位健康公司 | 高度可膨脹之聚合型薄膜及包含彼之組成物 |
JP6498177B2 (ja) | 2013-03-15 | 2019-04-10 | プロテウス デジタル ヘルス, インコーポレイテッド | 本人認証装置システムおよび方法 |
US10175376B2 (en) | 2013-03-15 | 2019-01-08 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
JP6511439B2 (ja) | 2013-06-04 | 2019-05-15 | プロテウス デジタル ヘルス, インコーポレイテッド | データ収集および転帰の査定のためのシステム、装置、および方法 |
US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
EP3047618B1 (de) | 2013-09-20 | 2023-11-08 | Otsuka Pharmaceutical Co., Ltd. | Verfahren, vorrichtungen und systeme zum empfang und zur decodierung eines signals in der gegenwart von rauschen mit slices und verzerrung |
WO2015044722A1 (en) | 2013-09-24 | 2015-04-02 | Proteus Digital Health, Inc. | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
US9492396B2 (en) | 2014-07-15 | 2016-11-15 | Yossi Gross | Enhanced drug delivery pill |
US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
US11432750B2 (en) * | 2016-03-14 | 2022-09-06 | Abbott Diabetes Care Inc. | In vivo enzyme activity sensors and methods |
KR102051875B1 (ko) | 2016-07-22 | 2019-12-04 | 프로테우스 디지털 헬스, 인코포레이티드 | 섭취 가능한 이벤트 마커의 전자기 감지 및 검출 |
AU2017348094B2 (en) | 2016-10-26 | 2022-10-13 | Otsuka Pharmaceutical Co., Ltd. | Methods for manufacturing capsules with ingestible event markers |
US11638837B2 (en) * | 2017-04-14 | 2023-05-02 | Mayo Foundation For Medical Education And Research | Apparatus for combined localization and dosimetry in image guided radiation therapy of the head and neck |
US11241562B2 (en) | 2018-03-13 | 2022-02-08 | Progenity, Inc. | Ingestible device with relatively large payload volume |
US10675248B2 (en) | 2018-08-14 | 2020-06-09 | Alma Therapeutics Ltd. | Expandable pill |
CN113663217A (zh) * | 2021-08-19 | 2021-11-19 | 杭州维纳安可医疗科技有限责任公司 | 增强肿瘤治疗场效果的电场发生系统、控制方法及装置 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4425117A (en) * | 1979-07-14 | 1984-01-10 | Battelle-Institut E.V. | Device for the release of substances at defined locations in the alimentary tract |
EP0510857A1 (de) * | 1991-04-23 | 1992-10-28 | Btg International Limited | Medikamentenabgabevorrichtung |
WO1994001165A1 (en) * | 1992-07-13 | 1994-01-20 | Elan Medical Technologies Limited | Medication administering device |
WO1994005361A1 (en) * | 1992-08-28 | 1994-03-17 | Cortrak Medical, Inc. | Polymer matrix drug delivery apparatus and method |
US5301688A (en) * | 1992-08-07 | 1994-04-12 | Physion S.R.L. | Method for localization and therapy of occult bladder cancer |
US5505700A (en) * | 1994-06-14 | 1996-04-09 | Cordis Corporation | Electro-osmotic infusion catheter |
DE19601487A1 (de) | 1996-01-17 | 1997-07-24 | Itt Ind Gmbh Deutsche | Vorrichtung zum Behandeln von malignen Gewebsveränderungen |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4003379A (en) * | 1974-04-23 | 1977-01-18 | Ellinwood Jr Everett H | Apparatus and method for implanted self-powered medication dispensing |
US4531524A (en) * | 1982-12-27 | 1985-07-30 | Rdm International, Inc. | Circuit apparatus and method for electrothermal treatment of cancer eye |
AU591171B2 (en) * | 1983-11-02 | 1989-11-30 | Alza Corporation | Dispenser for delivering thermo-responsive composition |
GB8422876D0 (en) * | 1984-09-11 | 1984-10-17 | Secr Defence | Silicon implant devices |
DE3705637A1 (de) * | 1987-02-21 | 1988-09-29 | Bissendorf Peptide Gmbh | Vorrichtung zur entfernung von lokal applizierten wirkstoffen gegen solide tumoren |
US5279607A (en) * | 1991-05-30 | 1994-01-18 | The State University Of New York | Telemetry capsule and process |
DE19601488C1 (de) * | 1996-01-17 | 1997-05-28 | Itt Ind Gmbh Deutsche | Verfahren zum Herstellen einer Meßeinrichtung sowie danach hergestellte Meßeinrichtung |
-
1997
- 1997-04-23 DE DE19717023A patent/DE19717023C2/de not_active Expired - Fee Related
-
1998
- 1998-04-11 WO PCT/EP1998/002133 patent/WO1998047561A1/de active IP Right Grant
- 1998-04-11 EP EP98921456A patent/EP0977614B1/de not_active Expired - Lifetime
- 1998-04-11 DE DE59812897T patent/DE59812897D1/de not_active Expired - Fee Related
- 1998-04-11 JP JP54494798A patent/JP2001523996A/ja active Pending
-
1999
- 1999-10-22 US US09/425,598 patent/US6245057B1/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4425117A (en) * | 1979-07-14 | 1984-01-10 | Battelle-Institut E.V. | Device for the release of substances at defined locations in the alimentary tract |
EP0510857A1 (de) * | 1991-04-23 | 1992-10-28 | Btg International Limited | Medikamentenabgabevorrichtung |
WO1994001165A1 (en) * | 1992-07-13 | 1994-01-20 | Elan Medical Technologies Limited | Medication administering device |
US5301688A (en) * | 1992-08-07 | 1994-04-12 | Physion S.R.L. | Method for localization and therapy of occult bladder cancer |
WO1994005361A1 (en) * | 1992-08-28 | 1994-03-17 | Cortrak Medical, Inc. | Polymer matrix drug delivery apparatus and method |
US5505700A (en) * | 1994-06-14 | 1996-04-09 | Cordis Corporation | Electro-osmotic infusion catheter |
DE19601487A1 (de) | 1996-01-17 | 1997-07-24 | Itt Ind Gmbh Deutsche | Vorrichtung zum Behandeln von malignen Gewebsveränderungen |
Non-Patent Citations (1)
Title |
---|
BRINTON, J.B.: "System to detect and treat cancer, using microwaves for both tasks.", ELEKTRONICS, no. 26, 1979, pages 42 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112007279A (zh) * | 2019-05-30 | 2020-12-01 | 淡海高级化妆品实验有限公司 | 手持抗皱的装置及皮肤护理的系统 |
Also Published As
Publication number | Publication date |
---|---|
EP0977614A1 (de) | 2000-02-09 |
US6245057B1 (en) | 2001-06-12 |
EP0977614B1 (de) | 2005-06-29 |
DE59812897D1 (de) | 2005-08-04 |
DE19717023A1 (de) | 1998-10-29 |
DE19717023C2 (de) | 2003-02-06 |
JP2001523996A (ja) | 2001-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0977614B1 (de) | Vorrichtung zum behandeln von malignen, tumorösen gewebebereichen | |
DE19601487C2 (de) | Vorrichtung zum Behandeln von malignen Gewebsveränderungen | |
DE60027720T2 (de) | Vorrichtung zur mikroporation eines biologischen gewebes mittels einer filmgewebe schnittstellenvorrichtung und verfahren | |
DE69919335T2 (de) | Vorrichtung zur erhöhung der flüssigkeitsdurchflussgeschwindigkeit in einem biologischen gewebe mit mikroporen | |
DE60106261T2 (de) | Abgabevorrichtung mit mikronadeln zur transdermalen verabreichung von einer substanz | |
Daugimont et al. | Hollow microneedle arrays for intradermal drug delivery and DNA electroporation | |
DE60306527T2 (de) | Implantierbares mems medikamentenverabreichungssystem | |
DE60219607T2 (de) | Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation | |
DE60125149T2 (de) | Infusionsstellenleckdetektionssystem | |
US10327644B2 (en) | Bio-chips and nano-biochips | |
EP2162183B1 (de) | Elektrophoretisches transdermales applikationssystem | |
EP1353654B1 (de) | Vorrichtungen und verfahren zur hitzepuls-gestützten transdermalen applikation von wirkstoffen | |
DE60016920D1 (de) | Arzneistoffverabreichungsystem zur verzögerten, völlstandigen wirkstoffabgabe im verdauungstrakt | |
Chen et al. | Implantable polymeric microneedles with phototriggerable properties as a patient-controlled transdermal analgesia system | |
US20100241059A1 (en) | Method and portable device for treating skin disorders | |
BRPI0616372A2 (pt) | dispositivo para fornecer um medicamento para um local de tratamento | |
EP1426024A1 (de) | Pflasterartige Chip-Systeme zur thermodynamischen Kontrolle topisch dermaler und transdermaler Systeme | |
WO2006005287A2 (de) | Kapsel zum freisetzen von in ihr befindlichen wirkstoffen an definierten orten in einem körper | |
EP1457233B1 (de) | Transdermales Wirkstoffverabreichungssystem mit Elektrodenraster | |
WO2002056862A2 (de) | Mikrosystem zur kontrolle der wirkstoffabgabe aus einem wirkstoffreservoir | |
WO1999052590A1 (de) | Transdermales applikationssystem (tds) mit elektrodenraster | |
EP0158310A2 (de) | Übertragungsgerät für Elektroakupunkturwirkungen | |
EP2636424A1 (de) | Therapeutisches System mit hohlen Mikronadeln | |
Sukanya et al. | Novel Approaches for Pulsatile Drug Delivery System | |
DE19713224A1 (de) | Elektro-Magnet-Pen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998921456 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09425598 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 544947 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998921456 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998921456 Country of ref document: EP |